{"id":"W2052054991","doi":"10.1182/blood-2012-02-410688","title":"A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia","year":2012,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":176,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Toronto","funders":"Canadian Cancer Society Research Institute; Ariad Pharmaceuticals; National Cancer Institute; National Institutes of Health; Pfizer; Oregon Health and Science University; Bristol-Myers Squibb","keywords":"Dasatinib; Medicine; Nilotinib; Imatinib; Internal medicine; Myeloid leukemia; Imatinib mesylate; Gastroenterology; Randomized controlled trial; Tyrosine-kinase inhibitor; Immunology; Cancer","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001330045,0.001220403,0.002011003,0.0003907787,0.0003459797,0.0008970517,0.0007286244,0.001286209,0.006558971],"category_scores_gemma":[0.001814787,0.0004984354,0.001151587,0.0003654076,0.001132903,0.000857651,0.0004784804,0.002427251,0.0008241566],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006655139,"about_ca_system_score_gemma":0.0008153901,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006528595,"about_ca_topic_score_gemma":0.001667073,"domain_scores_codex":[0.9993469,0.0004070537,0.00003935209,0.00008724549,0.0000404356,0.00007906162],"domain_scores_gemma":[0.9989748,0.0003063025,0.0002494198,0.00006637568,0.0000417314,0.0003614416],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9841803,0.002985322,0.0003270121,0.0002627826,0.000460226,0.00002647597,0.0000247177,0.000258749,0.001641133,0.0001345235,0.0006485339,0.009050149],"study_design_scores_gemma":[0.9680511,0.02989931,0.0008186634,0.00001307378,0.0001524153,0.00002157998,0.00001224702,0.0002460623,0.0001815359,0.0001293344,0.0004667634,0.000007945814],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9882541,0.002884437,0.0005019749,0.0009842691,0.0006343245,0.003153417,0.00100772,0.00009826302,0.002481508],"genre_scores_gemma":[0.9864489,0.001718351,0.00122641,0.00141581,0.0004101116,0.003588214,0.001191791,0.00001861551,0.00398172],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006558971,"threshold_uncertainty_score":0.02194196,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02894547002878551,"score_gpt":0.3226977424825182,"score_spread":0.2937522724537327,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}